Asciminib

Overview

Asciminib is a small molecule ABL kinase inhibitor developed for the treatment of chronic myeloid leukemia (CML). It represents a novel therapeutic approach by specifically targeting the ABL myristoyl pocket.

API suppliers (2)

Suppliers of Asciminib backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• Taiji Biopharmaceuticals Pvt. Ltd.India2 active DMF
• Hetero Labs LimitedIndia1 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (3 approved US products), the latest listed US patent on Asciminib expires 16 May 2040 and exclusivity 29 Oct 2031. Generic API sourcing typically opens up once these lapse.

Therapeutic areas